Purpose Breast cancers have a poorer prognosis if estrogen receptor expression was lost during recurrence. It is unclear whether this conversion is cell autonomous or whether it can be promoted by the microenvironment during cancer dormancy. We explored the ability of marrow-derived stromal cell lines to arrest co-cultured breast cancer cells and suppress estrogen receptor alpha (ER) expression during arrest, facilitating the emergence of estrogen-independent breast cancer clones. Methods Cancer cell growth, ER protein, microRNA, and mRNA levels were measured in breast cancer cell lines exposed to conditioned medium from marrow stromal lines in the presence and absence of estrogen and of signaling pathway modulators.
Introduction
Roughly 15% of metastatic estrogen receptor alpha (hereafter ER)-positive tumors convert to ER-negative status [1] with a resultant negative prognosis [2] . One study of disseminated tumor cells (DTC) in bone marrow aspirates identified only 28% concordance between ER expressions in primary tumors with that in DTC, suggesting that dormant micrometastases may lose ER expression at an even higher rate [3] . It is unclear whether this change in ER status is cell autonomous or is directed or sustained by signals in the microenvironment.
Conversion of cancer cells to ER-negativity may arise during cancer dormancy. Stromal cells have been reported to induce dormancy of metastatic breast cancer cells, as recently reported in a mouse model [4] . In a model of dormancy using MCF7 cells in ovariectomized mice, Ogba et al. [5] , reported that 25-30% of micro-metastatic cells had converted to an ER-negative status.
We hypothesized that ER-negative clones could be induced by paracrine signals from bone marrow stromal cells concurrent with growth arrest. ER loss can occur through transcription-associated proteolysis [6] , through epigenetic silencing [7] or transcriptional repression [8] of the ESR1 gene, through ubiquitin-or NEDD8-controlled proteasomal degradation [9] [10] [11] , or through translational inhibition by microRNAs [12] . Paracrine control of estrogen receptor alpha levels has been reported to occur through exosomal transfer of inhibitory microRNAs [13] or through hormones inhibiting ESR1 transcription (for review, [14] ). The importance of the microenvironment as a mediator of ER expression was recently underscored by the finding that intraductal injection of ER-positive cancer cells in a xenograft model preserved ER levels and a luminal phenotype, whereas fat pad injection suppressed ER expression and promoted a basal-like phenotype [15] .
HS5 cells are fibroblastic stromal cells derived from bone marrow [16, 17] that have been used to model cancer dormancy. The HS5 line is CD146-negative and expresses the CDCP1 CUB-domain protein, similar to a subset of marrow cells that are prevalent on biopsies [18] . This phenotypic similarity indicates that HS5 functionality may overlap the activity of a physiological subset of marrow stroma. HS5 have been used in combination with osteoblast and endothelial cells in a 3-D matrix to generate a growthinhibitory niche that suppressed the proliferation of cocultured luminal and basal breast cancer cell lines [19] . Secreted components from that mixture of cells were sufficient to inhibit growth [19] . HS5 cells also arrested T47 and MDA-MB-231 cells in spheroid co-culture [20] . In prostate cancer cells, paracrine BMP7 signaling by HS5 cells induced a dormant state, although a paracrine antiproliferative effect of this stromal line on breast cancer cells has not been reported.
We report that HS5 stromal cells suppressed estrogen receptor expression at multiple levels in MCF7 and T47D breast cancer cells and provided both pro-and anti-proliferative paracrine signals that functioned independently of ER expression. Blockade of the growth-suppressive stromal signaling pathway unmasked stromal promotion of estrogen-independent growth and anti-estrogen resistance in breast cancer cells. These results support a model through which marrow stroma directs the emergence of estrogen-negative metastases discordant with primary tumors.
Methods and materials Cells
MCF7, MDA-MB-231, HS5, HS27A, hFOB 1.19 (hFOB) cells were obtained from ATCC; T47D and BT474 breast cancer cells were obtained from Dr. Steffi Oesterreich (University of Pittsburgh). Cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 IU penicillin, and 100 lg/ml streptomycin (P/S). HS27A cells (from ATCC) and KM101 [21] (obtained from Michael Epperly, University of Pittsburgh) were initially carried in RPMI and then adapted to DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 IU penicillin, and 100 lg/ml streptomycin (P/S) prior to CM collection. MCF7 cells expressing tetracycline-inducible HA-tagged estrogen receptor or mCherry (from Dr. Sarat Chandarlapaty, Memorial Sloan Kettering Cancer Center) and hFOB cells were maintained in DMEM/F12 without phenol red, supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and P/S. Tet-inducible cells had G418 (100 lg/ml) and hygromycin (100 lg/ml) added. hFOB cells were incubated at 34°C, while all the other cell lines were incubated at 37°C. Fresh aliquots of cells were thawed for use every 2-3 months. Cells were routinely tested for mycoplasma. Conditioned medium was prepared as described in Supplemental Methods. Tandem repeat analysis was performed by Arizona Research Labs verifying MCF7, MDA-MB-231, HS5, HS27, T47D, hFOB 1.19 cells.
Reagents
Cytokines and pathways inhibitors used are described in Supplementary Table S1 . Antibodies used are listed in Supplementary Table S2 .
Cell proliferation assay
Breast cancer cells were plated in 96-well plates (black plate, clear bottom, Costar) at a low density (200-1000 cells/well in 100 ll medium) to highlight solitary cell behavior. Indicated treatments were replenished every 3 days. HS5-CM was added to 30% final volume based on pilot titrations for maximal effect, except where stated otherwise; an equivalent volume of complete medium or 30% CM from other stromal lines as indicated was added to control wells. In pilot experiments, there was no difference between the addition of complete medium or of MCF7-CM to experimental controls. Cell proliferation was measured at day 7 unless otherwise noted (for cells grown in complete growth medium) or day 14 (for cells in estrogen-free medium) using a fluorescence-based cell proliferation kit (CyQUANT, Life Technologies) following the manufacturer's instructions. These time points were optimal for a linear response of the CyQUANT assay when few cells are seeded. Fluorescence intensity (indicating cell numbers) was measured with a fluorescence 96-well plate reader (Beckman) at a wavelength of 480-520 nm. Each experimental replicate was done with 3-6 technical replicates.
Conditioned medium preparation
HS5 stromal cells at about 80% confluence cultured in T-75 flasks were fed with 10 ml fresh complete growth medium. After 3 days, this conditioned medium was harvested and spun at 10009g for 5 min, then filtered with 0.22 lm filter to remove cell debris. For estrogen-free conditioned medium, cells were washed with PBS three times and then fed with 10 ml fresh DMEM (without phenol red) supplemented with 5% charcoal-stripped serum. Conditioned medium was then aliquoted and stored at -80°C for future use. CM was generally used at 1 ml of conditioned medium per 800,000 HS5 cells. For experiment 2D, CM from each stromal line was adjusted to 1 ml of conditioned medium per 500,000 cells. As needed, CM aliquots were adjusted with culture medium to this concentration prior to freezing. Aliquots were thawed once and then discarded.
Charcoal stripping
Conditioned medium was charcoal stripped as indicated by addition of dextran-coated charcoal (Sigma C6241) added at 20 mg charcoal/ml media followed by gentle rocking overnight at 4°C. Subsequently, samples were spun for 15 min at 2000 g, and the collected supernatant was filtered through a 0.22-micron syringe filter.
Cell cycle analysis
Cell cycle analysis was conducted to show the relative proportion of MCF7 cells in each of the sub G1, G0/G1, S, G2/M phases in cells pre-synchronized with 1 lM nocodazole for 24 h. MCF-7 cells were grown in the presence or absence of 50% HS5-CM or KM101-CM for 24 h. Cells were then harvested, fixed in ice-cold 70% ethanol, and stored at 4°C. Fixed cells were stained for flow cytometric analysis with PI/RNase staining buffer, (BD Biosciences San Jose, CA, USA) and analyzed using a BD Accuri C6 flow cytometer and accompanying software (BD Biosciences, San Jose, CA, USA).
Estrogen-independent growth
To measure estrogen-independent growth, breast cancer cells were incubated for 2-3 days in estrogen-depleted medium consisting of phenol red-free DMEM (Life Technologies, Grand Island NY, catalogue number 31053-028) containing 5% charcoal-stripped fetal bovine serum (Sigma F6765) and 1% penicillin-streptomycin. Cells were then harvested with phenol red-free trypsin and plated into 96-well plates for CyQUANT assays or 24 well plates for crystal violet staining. For experiments measuring estrogen-independent growth in the presence of IL1RA and/or HS5-CM, these were added fresh every 3-4 days. For estrogen-free experiments, HS5 cells were grown in phenol red-free charcoal-stripped medium for 2-3 days prior to harvesting of HS5-CM. HS5-CM was added to 30% final volume, and equivalent medium was added to control wells.
Exosome preparation
Exosomes were prepared using differential centrifugation as described [22, 23] with modifications as noted in Supplemental Methods, and were confirmed for enrichment in the exosomal marker TSG101.
Western blotting and immunoprecipitations
Standard techniques were used; immunoprecipitations were performed using the Pierce Co-Immunoprecipitation kit (Cat: 26149, Thermo-Fisher, Rockford, IL, USA) according to manufacturer's instructions. For additional information, see Supplemental Methods. Estrogen-independent growth MCF7, T47D, and HS5 cells were treated in estrogen-depleted medium consisting of phenol red-free DMEM and charcoal-stripped fetal bovine serum for these experiments as detailed in Supplemental Methods.
Statistical analysis
Statistical analysis was conducted using tests as indicated, with results considered significant at the p \ 0.05 level. Binary comparisons used Student's t test; comparisons of experiments with three or more conditions used one-way ANOVA as indicated, using Tukey's post-test to control the Type I error rate in subsequent pairwise comparisons. For comparison of different stromal CM effects, ER protein decay rates, and for comparison of ICI dose response in the presence and absence of HS5-CM and IL1RA, mixed-effects models were used for analysis as noted in figure legends and detailed in Supplementary Statistical Methods.
Results

HS5 and hFOB cells inhibit growth of breast cancer cell lines through IL-1 signaling
In order to study whether growth-suppressive stroma comprises a favorable niche for loss of cancer cell estrogen receptor, we studied HS5 and other marrow stromal lines as mediators of quiescence and of shifts in estrogen-expression in cancer cells. The HS5 marrow-derived stromal line has been used to model dormancy in breast and prostate cancer [19, 24] and shares surface marker (CD105, CD73, CD44, CD90, data not shown) with mesenchymal stem cells (MSC's), also expressing a rarer marker (CDCP1) seen in a subset of marrow cells localized around bone [18] . While cell-cell contact with HS5 has been shown to inhibit breast cancer cell growth, we tested whether HS5-conditioned medium (HS5-CM) had growth-inhibitory activity by measuring the effect of HS5-CM on growth of three ER-positive cell lines using a fluorescence-based cell proliferation assay of breast cancer cells seeded at low density to highlight solitary cell behavior (CyQUANT, see ''Methods and materials'' section). Using this sensitive measure of growth inhibition, the HS5-CM was shown to inhibit the growth of MCF-7, BT474, and T47D cells (Fig. 1a) . Growth arrest was reversible, in that withdrawal of HS5-CM for 6 days allowed a resumption of growth, while maintaining cell sensitivity to re-added CM (Supplementary Figure S1 ).
We compared the effect on MCF7 growth of conditioned medium from HS-5 cells with CM from an equal number of KM101 cells [21] , another marrow-derived fibroblastic line that expresses (data not shown) surface markers CD73-and CD105. In contrast to HS5-CM, the CM from KM101 cells increased cancer cell growth. However, when growth-stimulatory CM was mixed with HS5-CM, the mixture inhibited MCF7 growth (Fig. 1b) . The dominant suppressive effect of HS5-CM on growth indicated an active function rather than the absence of stimulatory signals, suggesting that HS5 could model stromal components that enforce the cellular dormancy of bone metastases.
Growth inhibition was associated with the formation of p21-cdk2 complexes (Fig. 1c) and decreased Rb phosphorylation (Fig. 1d) . Dormant tumor cells have been characterized to have a low pErk1/2-to-phospho-p38 ratio [25] [26] [27] , and HS5 cell phosphorylation of p38 in co-cultured cancer cells has been linked previously to growth arrest by HS5 [19] . We observed durable upregulation of phospho-p38 in MCF7 cells exposed to HS5-CM (Fig. 1e) ; however, p38 activity was not required for HS5 to inhibit growth (Supplementary Figure S2) . Moreover, HS5-CM also increased phosphoErk such that the pErk1/2-to-phospho-p38 ratio was unaltered with growth arrest. In addition to pErk, HS5-CM also activated the AKT growth/survival pathway, durably phosphorylating AKT. AKT phosphorylation lasted for 7 days when growth assays were harvested (data not shown). Upregulation of AKT by HS5-CM could be inhibited by the IGF1/insulin receptor blocker OSI-906, implicating IGF1 as the paracrine activator of AKT (Fig. 1f) .
Given that growth arrest was sustained despite activation of signaling pathways associated with proliferation and survival, we sought to determine factors in the CM responsible for inhibiting MCF7 cell growth. HS5-CM has been previously reported to inhibit PC3 prostate cell proliferation via BMP7 in a Noggin-sensitive manner [24] .
However, we noted no reversal of HS5-CM suppression of MCF7 growth when using Noggin to block BMPs (Supplementary Figure S3) .
We assayed the HS5-CM for the expression of 39 cytokines as candidate growth inhibitors using Luminex assays. Of these, HS5-CM cytokines at ng/ml concentrations that were highly ([509) enriched compared with KM101-CM included GCSF, CXCL1, IL6, IL8, CCL2, CCL7, GMCSF; these did not inhibit MCF7 growth (data not shown). HS5-CM also contained IL1 (a, 120 pg/ml; b, 8 pg/ml) that has been reported to have growth-suppressive effects against MCF7 [28] .
In order to determine whether IL1 signaling accounted for the anti-proliferative effect of HS5-CM, we tested whether the IL1 antagonist IL1RA restored MCF7 growth in HS5-CM. IL1RA partially reversed growth suppression (Fig. 2a, d ) when added at a level that prevented both HS5- CM and IL1b from inducing lipocalin 2 (LCN2, a known target of IL1b [29] (Supplementary Figure S4A, B) ). The co-addition of IL1RA and HS5-CM increased cell cycling as manifest by fewer cells in G0/G1 and more cells in G2/ M phase (Fig. 2b) . IL1RA decreased HS5-CM induction of p21 and restored Rb hyperphosphorylation in HS5-CMtreated cells. Although IL1RA increased cell cycling, it did not prevent HS5 phosphorylation of p38, further indicating that growth inhibition was not maintained by p38 stress signaling (Supplemental Figure S4C) . We measured whether other bone marrow stromal cell CM's inhibited MCF7 growth in a IL1RA-sensitive way. These included CM from KM101 (above), the hFOB1.1.9 osteoblastic cell line [30] that had been combined with HS5 and HUVEC cells in a biomatrix rendering embedded breast cancer cells dormant in vivo [19] , and the HS27 cell line that had been co-derived from marrow with HS5 but differs in its cytokine profile and ability to support hematopoietic progenitor cells [16, 17] . Figure 2c demonstrates that each of these cell lines express IGF1 but that only HS5 and hFOB expressed IL1b.
The expression of IL1b correlated with the ability of stromal CM to suppress MCF7 growth. Figure 2d demonstrates that recombinant IL1b as well as HS5-CM and hFOB-CM inhibited MCF7 growth, whereas KM101-and HS27-CM did not. Suppressive CM was partially reversed nocodazole for 24 h prior to analysis. Data are expressed as mean ± SD of three independent experiments (day 5 n = 2, day 7 n = 1). There was no significant difference between any of the groups in the sub G1 phase. In S phase, only the comparison between control and HS5-CM-treated cells was significant, p = 0.040. All groups except for control compared to IL1RA were significantly different in the G0/G1 and G2/M phases (one-way Anova, Tukey post-test correction). c Immunofluorescence detection of IL1b (green) and IGF-1 (red) in stromal cells. d Effect of stromal CM's on MCF7 growth, with or without IL1-signaling blockade. Cells were treated on days 0 and 3 with IL1b (100 pg/ml) or with 30% CM from indicated stromal cells (adjusted to 1 ml CM per 500 K stromal cells) with or without IL1RA (50 ng/ml) as indicated. Three to four independent experiments shown, see Supplemental Methods for analysis. e Growth at 7 days of MCF7 or MDA-MB-231 cells exposed to HS5-or hFOB-CM (20%) or medium (DMEM, DMEM/F12, respectively) alone, or to 100 pg/ml or 100 ng/ml IL1b. Comparisons for each cell line by 1-way ANOVA with Tukey's correction for multiple comparisons. Two independent experiments. *p \ 0.05, **p \ 0.01, ***p \ 0.001 by IL1RA, confirming IL1 as contributor to paracrine growth inhibition by both HS5 and hFOB. Figure 2e demonstrates that sensitivity to IL1b distinguishes the HS5-CM-suppressed MCF7 cells from non-suppressed MDA-MB-231 cells.
Estrogen receptor alpha protein destabilization by conditioned medium from HS5 cells
Having established that the HS5 secretome was growth-inhibitory, we proceeded to investigate its effect on ER expression. We measured whether HS5-CM inhibited the expression of ER, comparing it to CM from the other stromal cell lines used in growth assays. Figure 3a and b, respectively, demonstrate the loss of ER by immunofluorescence and by immunoblotting in MCF7 cells exposed for 16 h to HS5-CM. ER protein levels were decreased on average by 9.9-fold by HS5-CM (n = 11) and to a lesser extent (2.9-fold, n = 4) by hFOB-CM. Notably, hFOB-CM caused phosphorylation of Akt, pErk, and p38 in MCF7, similarly to HS5-CM ( Fig. 3a ; Supplemental Figure S8D ). Conditioned medium from KM101 and HS27A cell lines had minimal effect on ER levels in MCF7. The KM101-and HS27A-CM did not phosphorylate p38 (Fig. 3a) , unlike the CM's that suppressed ER. This suggested that the p38 pathway could be involved in stromal suppression of ER. However, neither the SB20358 nor SB202190 p38 inhibitors (added 10 min prior to CM at 10 lM) prevented ER suppression by HS5-CM (Fig. 3c) . This indicated that p38 pathway activation was unlikely to mediate ER suppression.
Because exosomes from fibroblasts in primary ERnegative tumors have been reported to suppress ER expression [13] , we also tested whether exosomes from HS5 mediated the observed downregulation of ERs. Figure 3d demonstrates that HS5 exosomes (HS5 exo) did not mediate ER suppression. We tested whether HS5-CM destabilized ER alpha protein. The ability of the proteasome inhibitor MG132 to restore ER protein expression in HS5-CM-treated breast cancer cells (Fig. 4a) indicated that the stability of the estrogen receptor protein could be compromised by the stromal cell CM. Figure 4b demonstrates increased ubiquitination of immunoprecipitated estrogen receptor from MCF7 cells exposed to HS5-CM, compared to control medium. Consistent with this, HS5-CM exposure increased high molecular weight forms evident in long exposure of ER immunoblots (Supplemental Figure S5a) . Global proteasome activity did not change with HS5-CM exposure (Supplemental Figure S5b) . We measured MCF7 ER levels in the presence of cycloheximide with or without HS5-CM to determine decay rates. Destabilization of ER by HS5-CM is shown in Fig. 4c (representative Western blots in Fig. 4d, Supplemental Figure S5 ). The degradation rate is compatible with a decrease in the calculated half-life of ER from 10.72 h (95% confidence interval 9.19, 12.59) in the absence of HS5-CM to 3.76 h (95% confidence interval 3.44, 4.00) in the presence of HS5-CM (p = 0.008, mixedeffects analysis of covariance model). In addition to tripling the degradation rate of ER protein, HS5-CM also lowered the level of MCF7 mRNA (3.9-fold by qPCR).
Unlike growth arrest, the inhibition of ER transcript did not require IL1 (Fig. 4e) .
It was conceivable that the estrogen or estrogenic compounds produced by HS5 cells could explain the enhanced ER degradation in cells exposed to HS5-CM. However, ER levels continued to be suppressed by HS5-CM subjected to charcoal stripping to remove estrogens (data not shown). Moreover, transcription-associated ER phosphorylation (S118) was decreased by HS5-CM treatment and the addition to MCF7 of HS5-CM did not activate expression of a 3X-ERE-luc reporter sensitive to ligand activation of ER signaling (Supplementary Figure S6) . The lack of ligand-induced signaling indicates that ligand-induced ER loss was unlikely.
Estrogen receptor suppression does not depend on HS5-upregulated microRNAs
Fibroblasts from ER-negative tumors have been found to inhibit expression of ER in MCF7 by exosomal transfer of miR221/222 [13] , and miR 221/222 expression in MDA-MB-268 breast cancer line suppresses ER translation [12] . Exosomal miR transfer in HS5-CM was unlikely because HS-5 exosomes did not suppress ER. However, we found that miR222 was elevated twofold in MCF7 cells exposed to HS5- Table S3 ), raising the prospect that miRs upregulated by HS5-CM contributed to ER loss independently of ubiquitin-mediated turnover. In fact, HS5-CM lowered by *35% the expression of a luciferase reporter under the control of the ER 3 0 -UTR which is the site of miR action. However, inhibition of miR222 and other HS5-upregulated miRs (miR 132, 29a, 29b) did not prevent HS5-CM from suppressing ER, indicating that miRs, if involved, were a minor contributor to this paracrine downregulation of ER ( Supplementary Figure S7) . In addition to blocking these microRNAs, inhibitors of multiple pathways that have been linked to ER downregulation were tested but did not reverse ER loss in MCF7 exposed to HS5 and/or hFOB-CM (Supplemental Figure S8) .
Uncoupling of growth arrest and ER downregulation
A reasonable presumption is that ER downregulation accounted for the growth arrest of MCF7 cells by HS5-CM.
Given that HS5-CM suppressed growth largely through IL1, it would follow that IL1 contributed to ER loss and that forced ER expression would prevent arrest by HS5 CM or IL1. We found, however, that addition of IL1 did not suppress ER protein (Fig. 5b) . Moreover, IL1RA restored growth to HS5-CM-treated cells (Fig. 2) without re-expression of ER (Fig. 5a, b; Supplementary Figure S8 ). IL1RA did not alter induction of phospho-Akt, Erk, or p38 by HS5-or hFOB-CM (Fig. 5c) ; our data link those pathways to HS5-CM effects on growth (below) but not to ER loss (Supplemental Figure S8D ) in MCF7. In order to determine whether exogenous ER could rescue cells from HS5-mediated growth arrest, we stably transfected MCF7 cells with a GFP-ER fusion protein. The GFP-positive population expressed ER at a high level, with continued expression after HS5-treatment. Nonetheless, these ERexpressing cells also were growth-arrested when exposed to the conditioned medium (Fig. 5d) . We confirmed that ER expression could not rescue growth in HS5-CM-treated MCF7 in experiments using tetracycline-inducible HAtagged ER (Fig. 5e, f) . These findings indicated that a decrease in ER was not necessary or sufficient for HS5-mediated growth arrest.
Estrogen-independence of HS5-CM-primed luminal breast cancer cell lines rescued from IL1 growth suppression
Because ER expression remained low in HS5-CM-treated cancer cells in which IL1RA rescued growth, we investigated whether these rescued cells exhibited a reduced dependence on estrogen.
We assayed the growth in estrogen-depleted medium of MCF7 and T47D cells in the presence or absence of IL1RA and/or of CM from HS5 cultured in estrogen-depleted medium. The cells exposed to HS5-CM combined with IL1RA had a growth advantage in the absence of estrogen (Supplemental Figure S9) . Under conditions of estrogen depletion, HS5-CM repressed ER and activated MEK/ ERK, AKT, and p38 MAPK pathways (Fig. 6a) , similar to the findings in estrogen-replete culture (Fig. 1e) . To further investigate the requirement for AKT, p38, and ERK activation in stromal CM promotion of MCF7 estrogen-independent growth, we added pathway inhibitors to MCF7 cells exposed to HS5-CM and IL1RA under estrogen-free conditions. This is shown by crystal violet staining (Fig. 6b) and quantitation of staining in Fig. 6c . The AKTinhibitor perifosine prevented MCF7 outgrowth under these conditions. We additionally tested whether the IGF1 inhibitor OSI-906 (linsitinib) that blocked AKT activation also prevented MCF7 growth in HS5-exposed, IL1-blocked MCF7. It appeared that IGF1/insulin signaling was required for HS5-CM to augment growth of MCF7 in the Fig. 6 HS5-CM supports estrogen-independent growth when IL1 is blocked. a Effect of IL1RA and HS5-CM on indicated proteins in estrogen-free medium; cells were pre-incubated in estrogen-free medium for 2 days and treated as indicated for 2 days before harvest. b Crystal violet staining of MCF7 growth (4000 cells seeded) under estrogen-free conditions with or without HS5-CM, IL1RA, or both, in the presence of inhibitors directed at AKT (perifosine, 5 lM), MEK/ ERK (U0126), p38 (SB203580, 2 lM), or IGF1R (OSI906, 1 lM) pathways. c Quantitation of crystal violet staining, experiments as in B; HS5-CM plus IL1RA indicated by HI. Analysis by mixed-effects ANOVA, mean ± SEM shown, n = 8 independent experiments; pairwise comparisons between treatments were adjusted for multiplicity by Westfall's method (see Supplemental Methods). *p \ 0.05, **p \ 0.01, ***p \ 0.001 absence of estrogen. MEK/ERK signaling was also involved in the promotion of estrogen-independent growth, given that the MEK inhibitor U0126 prevented the stimulation of growth. In contrast, p38 was not required for the outgrowth of the estrogen-independent cells since IL1RA-augmented growth was unencumbered by the p38-inhibitor SB203580 (Fig. 6c) .
Fulvestrant resistance of stromal CM-primed luminal breast cancer cell lines rescued from IL1 growth suppression
Given the enhanced ability of HS5-CM/IL1RA-treated MCF7 and T47D cells to grow in estrogen-depleted conditions, we explored whether these treatments sustained growth in the presence of the ER degrader ICI 182,780 (fulvestrant) that is used for cancer recurrence or for progression through anti-estrogen therapy. Cells cultured in complete medium were seeded for growth assays in the presence of vehicle, HS5-CM, IL1RA or HS5-CM, and IL1RA. A dose-response assay for growth was performed using fulvestrant (ICI). The addition of IL1RA to HS5-CM increased growth as expected. ICI was less effective against T47D and MCF7 cells when they were exposed to HS5-CM or to the combination of HS5-CM and IL1RA as was evident by the significantly blunted dose-response slope relative to control (no additions) or to IL1RA alone (Fig. 7) . The data indicate that ER suppression in HS5-CM cells was sufficient to undermine the responses to ER-targeted treatment when the cells were released from growth suppression by IL1RA.
Discussion
This study reports increased degradation of ER protein in breast cancer cells exposed to the secretome of HS5 stromal cells, a cell line with functional [16, 17] and phenotypic [18] similarities to marrow stromal cells present in biopsies. Cancer cells exposed to this conditioned medium were growth-arrested. Unexpectedly, the growth arrest did not result from ER loss, but was mediated primarily by IL1 in the CM. Our results would support the possibility that ER-negative metastases arising from ER-expressing disseminated tumor cells undergo conversion in response to paracrine signals while arrested in the bone microenvironment. Given the prognostic importance of ER loss in recurrent disease [2] , it is important to distinguish cell autonomous versus microenvironment-mediated contributions to this phenotypic shift.
Conditioned medium from HS5 cells increased ubiquitination of ER in MCF7 cells and lowered ER levels in a proteasome-dependent manner. We have noted upregulation of multiple proteasome component genes in a preliminary investigation of the HS5-CM-induced transcriptome (data not shown) and considered whether proteosomal activity was globally increased. However, no difference in 20S proteasome activity occurred with MCF7 treatment by HS5-CM. Investigation of ER-specific ubiquitination/degradation pathways is underway. ER loss was augmented by a decrease in ER mRNA in MCF7 cells after HS5-CM treatment. We have investigated whether cytokines that have been reported to inhibit transcription of the ER gene-EGF [31] , IGF-1 [32] , Oncostatin M [33] , FGF7 [34] , TGFb [35] , BMP7 [36] , or IL1 [37, 38] -mediated the inhibitory effect of HS5-CM on ER but could not link the ER loss to any of these cytokines using neutralizing antibodies or specific inhibitors (Supplemental Figure S8 ). We recently became aware that while this project was underway, Lang et al. [39] reported loss of ER-positive fluorescent staining in MCF7 cells exposed to HS5 co-culture in microfluidic channels under estrogen-free conditions. They ascribed ER loss to paracrine activation of ER signaling. This is less likely under our conditions in which HS5-CM-lowered transcriptionassociated ER-S118 phosphorylation (in contrast to [39] ), did not activate an ERE-reporter in MCF7 and suppressed ER whether HS5-CM was charcoal-stripped or not, or whether the medium contained estrogen or not. Concurrent with ER loss, ER-positive breast cancer cell lines (MCF7 and T47D) underwent growth arrest when exposed to CM from HS5 and hFOB cells. This extends prior reports that mixed HS5/hFOB/breast cancer cell coculture inhibited breast cancer growth [19, 20] .
Cancer cells arrested by stromal CM had concurrent stromal activation of MEK/ERK and AKT pathways that facilitated escape from quiescence when IL1 signaling was blocked; in essence the cells were primed for later growth. MEK/ERK and AKT signaling pathways figure prominently in ER-mediated proliferation and are activated through various means in cells escaping dormancy or antiestrogen treatment [40] [41] [42] [43] . In our study, these activated pathways were necessary to increase estrogen-independent growth of the MCF7 cells. Cancer cell outgrowth in estrogen-depleted conditions therefore only required blockade of anti-proliferative stromal signals and paracrine activation of MEK/ERK and AKT signaling and so did not require re-expression of ER.
The stromal CM support of estrogen-independent MCF7 or T47D growth that we observed is compatible with in vivo studies in which co-injection of cancer-activated stromal fibroblasts [44] or of a mesenchymal stem cell subset [45] with MCF7 rendered the cells hormone-independent in xenograft models.
A limitation of this in vitro study is that these in vitro results do not clarify why ER loss only occurs in a subset of bone metastatic cancer. It is possible that cells lose ER during the metastatic process rather than dormancy, seeding ER-negative cells from ER-heterogeneous primary tumor or losing ER during epithelial mesenchymal transition early in metastasis [8] . ER could be lost because of cancer-autonomous mutations (e.g., p53 [46] ) at a point in the metastatic process. Alternatively, in keeping with our results, cancer cells that convert could have associated stochastically with a distinct subset of stromal cells that induce ER loss. We are examining whether surface markers shared by ER-suppressing (HS5, hFOB) but not non-suppressing (KM101, HS27A) stromal cell lines are indicators of a suppressive capability. Ultimately, it will be necessary to identify the marrow stromal subset sharing the HS5 phenotype and function and demonstrate its co-localization with ER-negative but not ER-positive metastatic cells in clinical samples.
We showed that growth arrest involved paracrine IL1 from HS5 or from the pre-osteoblastic stromal line hFOB.
IL1 has been variably reported to inhibit [28, 38, 47] or to promote [48] MCF7 growth. In our study, the ability of the IL1 receptor antagonist (IL1RA) to reverse growth arrest confirmed IL1 as a paracrine inhibitor of cancer cell growth by HS5 and by osteoblastic hFOB stromal cells. The osteoblastic niche supports quiescent hematopoietic stem cells and is targeted for colonization by competing cancer cells [49] . Replicative marking of melanoma [50] and myeloma [51] cells has shown osteoblasts to support rare quiescent cancer cells. It has been established that metastatic breast cancer cells home to the osteoblastic niche and that it can provide a suitable environment for growth [43] . Whether disseminated breast cancer cells exploit this niche during dormancy and whether localized IL1 is engaged in the commitment to dormancy or whether stromal IL1 signals are inhibited by growth stimuli in vivo will require further study.
The growth-suppressive role of IL1 in HS5-CM that we report adds to the findings of other (p38, ALK5-dependent) growth-inhibitory pathways activated during cell-cell contact of HS5 cells with SUM159 breast cancer cells [19] . Our inhibitor experiments appeared to rule out p38 as a mediator of the paracrine suppression of MCF7 or T47D growth by HS5. Although a low phospho-Erk/phospho-p38 ratio has been validated as a determinant of dormancy in such in vitro models and subsequently in vivo [25] , we demonstrated that stromal-derived IL1 is capable of arresting cells in which both pErk and p-p38 are high. Additionally, high levels of phospho-p38 did not prevent cycling when IL1 was blocked. Given that we focused on paracrine signaling, it is possible that cell-cell interactions engage additional pathways such that p38 becomes a necessary and dominant mediator of IL1 effects or that cellcell signals uncouple IL1 from growth control.
Growth arrest was not secondary to downregulation of ER in the MCF7 or T47D cells exposed to HS5-CM. Although one report has indicated that high-dose IL1 (*109 the concentration in HS5-CM) inhibited growth and lowered ER by 40% in MCF7 [37, 38] , our data showed that IL1 contributed to growth inhibition but was not involved in ER downregulation. ER remained low when IL1 signaling was blocked. Exogenous ER could not rescue growth, whereas IL1 receptor antagonist could, indicating ER-independent growth arrest. It is notable that ER downregulation did not contribute to growth arrest, suggesting that disseminated cancer cells do not depend on anti-ER treatment to exit the cell cycle in inhibitory microenvironments.
IL1 receptors and IL1/IL1RA cytokines have been identified in the primary tumor microenvironment in human breast cancer [52] . IL1 has been associated with either a pro-tumorigenic or anti-tumorigenic inflammatory environment in vivo. For instance, tumor growth of MCF xenograft implants stably expressing IL1a exceeds that of controls [53] , and knockout mice for IL1a and b are resistant to syngeneic melanoma angiogenesis and spread [54] . In contrast, exogenous IL1a and b inhibit syngeneic tumor growth [55] [56] [57] .
It is possible that IL1 contributes to quiescence of disseminated cancer cells in bone (as opposed to BMP-mediated quiescence that was shown to occur in lung but not bone metastases [58, 59] ), and that loss of IL1-signaling facilitates emergence from quiescence. Although stromal cell and hematopoietic cell production of IL1 ex vivo has been described [60] , there is little information on IL1 expression by stroma in the endosteal niche targeted by bone metastatic breast cancer. Our data demonstrating that stromal IL1 is anti-proliferative are consistent with data about prolonged relapse-free survival associated with high IL1b-expressing tumors in 1802 ER? breast cancer patients [61] (IL1b, 39402_at, using the online survival tool kmplot.com/breast, accessed 10/11/2016). A suppressive role for IL1 in human breast cancer relapse is also supported by a recent report that stromal IL1b expression is correlated with longer relapse-free and overall survival in breast carcinomas [62] . An analysis of women with favorable Mammaprint profiles of primary breast tumors found IL1b and IL1R1 to be associated with non-recurrence [63] . A caveat is that the applicability of IL1 expression levels in tumors to that in the microenvironment of disseminated cancer cells is tenuous.
The HS5 and hFOB stromal cells produced not only growth-inhibitory IL-1 but also IGF1 that selects for bone metastatic clones [64] and activates AKT, a driver of micrometastases [43] . IGF1, pERK, and pAKT were required for outgrowth of (ER-suppressed) clones but only did so if suppressive IL1 was blocked. The dominant effect of IL1 raises the possibility that IL1 is a contributor to dormancy of disseminated luminal breast cancer cells in bone. In that case, forced exit from dormancy using IL1RA could render otherwise chemoresistant dormant cells sensitive to therapy. Mouse models have shown IL1RA to be anti-tumorigenic; on the other hand, high circulating IL1RA has been observed in cancer patients and linked to tumor load (reviewed in [65, 66] ). We note that pretreatment with IL1RA enhanced melanoma sensitivity to chemotherapy in mice [67] . Clinical trials using IL1RA (anakinra, Kineret) as adjuvant therapy in metastatic breast (NCT01802970) or other (NCT01624766, NCT02550327, NCT02090101) cancers are under way.
It would be interesting if our finding of both pro-and anti-oncogenic paracrine signaling from a bone marrow stromal line recapitulates an in vivo function of HS5-like stromal cells in the disseminated tumor cell setting. In such a case, the growth-arrested state would represent a ''yinyang'' situation in which latent oncogenic capabilities masked by dormancy and new phenotypes (such as ER suppression) can manifest once growth is initiated.
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